Greenwich LifeSciences, Inc. (GLSI) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Greenwich LifeSciences, Inc. on December 19, 2024. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol GLSI. A total of 12,848,165 shares were represented at the meeting, constituting a quorum.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Voting Results
Three proposals were submitted to stockholders, all of which were approved:
- Proposal 1 (Director Elections): All five nominees were elected to serve until the 2025 Annual Meeting. No votes were cast against any nominee.
- David McWilliams: 7,824,313 For
- Snehal S. Patel: 8,052,306 For
- Eric Rothe: 7,849,736 For
- F. Joseph Daugherty, M.D.: 7,987,061 For
- Kenneth Hallock: 7,852,855 For
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of RBSM, LLP as the independent registered public accounting firm for the fiscal year ended December 31, 2024.
- For: 9,224,694
- Against: 10,077
- Abstain: 2,644
- Proposal 3 (Equity Plan Amendment): Stockholders approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares reserved for issuance from 1,500,000 to 4,000,000 shares.
- For: 8,067,672
- Against: 164,730
- Abstain: 5,043
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that the 2019 Equity Incentive Plan share reserve has officially increased to 4,000,000 shares.
- Verification of the new board composition following the election of the five directors.
- Confirmation that RBSM, LLP is the appointed auditor for the fiscal year ending December 31, 2024.
- Review of the Definitive Proxy Statement filed on November 1, 2024, for detailed background on the proposals.